Program:
Co-sponsored by: Canji, Inc. and Pharmacia Biotech
Co-organized by: PharmaGenics
Co-sponsoring Journals: Cancer Gene Therapy, Cancer Genetics Report, and Oncogene
The p53 gene is recognized as one of the most important genes in the cancer field. One role of p53 is
to proofread for genetic damage and eliminate cells in which unrepaired genetic errors appear.
Unfortunately, p53 itself is quite sensitive to point mutations in that virtually all mutations lead to a loss
of function. This program focuses on advances in understanding and use of p53 for diagnostic and
therapeutic purposes. With approximately half of all cancers involving the loss of functional p53, the
identification of such mutations can be a significant diagnostic tool. Gene therapy, vaccines, and small
molecule drugs aimed at restoring p53 activity, or other strategies based on p53, offer the potential
of valuable new tools for cancer treatment.
Registration :
Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls, MA 02164
USA
Phone: 617-630-1300
Fax: 617-630-1325
Deadline for Abstracts: 03/28/97
Email for Requests and Registration: chi@healthtech.com